(RHP) Ryman Hospitality Properties - Ratings and Ratios
Convention Resorts, Entertainment Venues, Music Brands, Festival Business
Dividends
| Dividend Yield | 4.69% |
| Yield on Cost 5y | 8.25% |
| Yield CAGR 5y | 47.12% |
| Payout Consistency | 50.7% |
| Payout Ratio | 118.7% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 23.1% |
| Value at Risk 5%th | 35.8% |
| Relative Tail Risk | -5.91% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.45 |
| Alpha | -26.63 |
| CAGR/Max DD | 0.26 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.551 |
| Beta | 0.964 |
| Beta Downside | 0.754 |
| Drawdowns 3y | |
|---|---|
| Max DD | 32.07% |
| Mean DD | 10.19% |
| Median DD | 11.10% |
Description: RHP Ryman Hospitality Properties November 05, 2025
Ryman Hospitality Properties, Inc. (NYSE:RHP) is a REIT that owns and leases upscale, convention-center hotels-including five of the seven largest non-gaming convention hotels in the U.S.-and a controlling stake (~70%) in Opry Entertainment Group, which operates iconic country-music venues and related entertainment assets. The hotel portfolio, managed by Marriott International, comprises 12,364 rooms and over 3 million sq ft of indoor/outdoor meeting space across seven flagship Gaylord resorts and two JW Marriott properties.
Key performance indicators to watch: (1) RevPAR for the Gaylord and JW Marriott hotels has been trending upward, rising ~5% YoY in Q2 2024 as corporate travel rebounds and large-scale events resume; (2) occupancy across the portfolio sits near 78%, still below the pre-pandemic 85% benchmark, indicating upside potential if MICE demand accelerates; (3) the REIT’s net debt-to-EBITDA ratio is approximately 5.2×, reflecting a leveraged balance sheet that is sensitive to rising interest rates. Primary economic drivers include corporate travel spend, U.S. business-event (MICE) growth rates, and the Fed’s monetary policy, which together influence both hotel revenue streams and the cost of financing.
If you’re looking to deepen your analysis of RHP’s valuation dynamics, a quick look at ValueRay’s metric breakdown can surface hidden risk factors and upside catalysts worth exploring further.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income (238.4m TTM) > 0 and > 6% of Revenue (6% = 149.2m TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA 1.41pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 11.74% (prev 8.35%; Δ 3.39pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.10 (>3.0%) and CFO 592.6m > Net Income 238.4m (YES >=105%, WARN >=100%) |
| Net Debt (3.65b) to EBITDA (747.1m) ratio: 4.89 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.47 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (65.5m) change vs 12m ago 2.44% (target <= -2.0% for YES) |
| Gross Margin 31.19% (prev 30.81%; Δ 0.38pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 43.63% (prev 44.67%; Δ -1.04pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.06 (EBITDA TTM 747.1m / Interest Expense TTM 457.2m) >= 6 (WARN >= 3) |
Altman Z'' 0.19
| (A) 0.05 = (Total Current Assets 907.9m - Total Current Liabilities 615.8m) / Total Assets 6.20b |
| (B) -0.15 = Retained Earnings (Balance) -931.5m / Total Assets 6.20b |
| (C) 0.08 = EBIT TTM 482.4m / Avg Total Assets 5.70b |
| (D) -0.19 = Book Value of Equity -943.9m / Total Liabilities 4.99b |
| Total Rating: 0.19 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 64.18
| 1. Piotroski 4.0pt |
| 2. FCF Yield 3.34% |
| 3. FCF Margin 12.84% |
| 4. Debt/Equity 5.45 |
| 5. Debt/Ebitda 4.89 |
| 6. ROIC - WACC (= 3.59)% |
| 7. RoE 36.12% |
| 8. Rev. Trend 78.94% |
| 9. EPS Trend 47.86% |
What is the price of RHP shares?
Over the past week, the price has changed by +6.81%, over one month by +3.79%, over three months by -0.95% and over the past year by -11.13%.
Is RHP a buy, sell or hold?
- Strong Buy: 10
- Buy: 3
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the RHP price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 112.4 | 14.7% |
| Analysts Target Price | 112.4 | 14.7% |
| ValueRay Target Price | 109.4 | 11.6% |
RHP Fundamental Data Overview December 03, 2025
P/E Trailing = 24.828
P/E Forward = 26.2467
P/S = 2.3873
P/B = 7.8222
P/EG = 1.38
Beta = 1.23
Revenue TTM = 2.49b USD
EBIT TTM = 482.4m USD
EBITDA TTM = 747.1m USD
Long Term Debt = 3.98b USD (from longTermDebt, last quarter)
Short Term Debt = 9.07m USD (from shortTermDebt, last fiscal year)
Debt = 4.13b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.65b USD (from netDebt column, last quarter)
Enterprise Value = 9.56b USD (5.91b + Debt 4.13b - CCE 483.3m)
Interest Coverage Ratio = 1.06 (Ebit TTM 482.4m / Interest Expense TTM 457.2m)
FCF Yield = 3.34% (FCF TTM 319.4m / Enterprise Value 9.56b)
FCF Margin = 12.84% (FCF TTM 319.4m / Revenue TTM 2.49b)
Net Margin = 9.58% (Net Income TTM 238.4m / Revenue TTM 2.49b)
Gross Margin = 31.19% ((Revenue TTM 2.49b - Cost of Revenue TTM 1.71b) / Revenue TTM)
Gross Margin QoQ = 29.45% (prev 32.94%)
Tobins Q-Ratio = 1.54 (Enterprise Value 9.56b / Total Assets 6.20b)
Interest Expense / Debt = 7.03% (Interest Expense 290.5m / Debt 4.13b)
Taxrate = -11.98% (negative due to tax credits) (-3.63m / 30.3m)
NOPAT = 540.2m (EBIT 482.4m * (1 - -11.98%)) [negative tax rate / tax credits]
Current Ratio = 1.47 (Total Current Assets 907.9m / Total Current Liabilities 615.8m)
Debt / Equity = 5.45 (Debt 4.13b / totalStockholderEquity, last quarter 758.5m)
Debt / EBITDA = 4.89 (Net Debt 3.65b / EBITDA 747.1m)
Debt / FCF = 11.43 (Net Debt 3.65b / FCF TTM 319.4m)
Total Stockholder Equity = 659.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.85% (Net Income 238.4m / Total Assets 6.20b)
RoE = 36.12% (Net Income TTM 238.4m / Total Stockholder Equity 659.9m)
RoCE = 10.41% (EBIT 482.4m / Capital Employed (Equity 659.9m + L.T.Debt 3.98b))
RoIC = 12.46% (NOPAT 540.2m / Invested Capital 4.34b)
WACC = 8.87% (E(5.91b)/V(10.05b) * Re(9.57%) + D(4.13b)/V(10.05b) * Rd(7.03%) * (1-Tc(-0.12)))
Discount Rate = 9.57% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.40%
[DCF Debug] Terminal Value 76.44% ; FCFE base≈269.7m ; Y1≈328.6m ; Y5≈544.7m
Fair Price DCF = 112.3 (DCF Value 7.07b / Shares Outstanding 63.0m; 5y FCF grow 23.34% → 3.0% )
EPS Correlation: 47.86 | EPS CAGR: 28.87% | SUE: 0.16 | # QB: 0
Revenue Correlation: 78.94 | Revenue CAGR: 12.78% | SUE: 0.87 | # QB: 3
EPS next Quarter (2026-03-31): EPS=1.02 | Chg30d=+0.200 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=4.48 | Chg30d=+0.840 | Revisions Net=-1 | Growth EPS=+10.9% | Growth Revenue=+8.1%
Additional Sources for RHP Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle